Precision Medicine News and Research

RSS

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application for pertuzumab and granted Priority Review.

8 Feb 2012

Roche’s new breast cancer drug Pertuzumab up for FDA review

U.S. health regulators, the Food and Drugs Administration (FDA) has granted a priority review for an experimental Roche breast cancer drug that in clinical trials added six months to the time before the disease worsened. Pertuzumab approval decision is due by June 8th this year. It could be used with Herceptin in HER2-positive patients. This was announced by Roche Holding AG's Genentech unit on Tuesday.

7 Feb 2012

Vending machine to dispense “morning after pills” at college sparks debate

Now students at Shippensburg University in Pennsylvania can get the “morning after” pill by sliding $25 into a vending machine, an idea that has drawn the attention of federal regulators and raised questions about how accessible emergency contraception should be.

7 Feb 2012

TGen to host Pediatric Cancer Translational Genomics in Scottsdale

The Translational Genomics Research Institute (TGen) will host Pediatric Cancer Translational Genomics Feb. 6-8 at the Hotel Valley Ho in Scottsdale, bringing together more than 150 leading pediatric cancer researchers, clinicians and foundations to promote the exchange of information and ideas for advancing pediatric cancer research and treatment.

7 Feb 2012

Whole exome sequencing provides clues about rare mutations in aneurysms

An innovative approach to genome screening has provided clues about rare mutations that may make people susceptible to brain aneurysms, predisposing them to brain bleeds, according to preliminary late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

4 Feb 2012

Positive updated results from Aeterna Zentaris' AEZS-108 Phase 1 trial on CRPC

Aeterna Zentaris Inc. today reported positive updated results for the Phase 1 portion of its ongoing Phase 1/2 study in castration- and taxane-resistant prostate cancer (CRPC) with AEZS-108 (zoptarelin doxorubicin), the Company's targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analog.

4 Feb 2012

Scientists establish HCV infection in liver-like cells derived from iPSCs

Hepatitis C, an infectious disease that can cause inflammation and organ failure, has different effects on different people. But no one is sure why some people are very susceptible to the infection, while others are resistant. Scientists believe that if they could study liver cells from different people in the lab, they could determine how genetic differences produce these varying responses. However, liver cells are difficult to obtain and notoriously difficult to grow in a lab dish because they tend to lose their normal structure and function when removed from the body.

2 Feb 2012

Canadian Government announces investment in personalized medicine

The Harper Government today announced an important investment that will help Canadians in getting more effective treatments and make the healthcare system more sustainable through personalized medicine.

1 Feb 2012

Researchers use liquid laser to diagnose genetic mutations linked with cancer

Using a liquid laser, University of Michigan researchers have developed a better way to detect the slight genetic mutations that might predispose a person to a particular type of cancer or other diseases.

1 Feb 2012

Dana-Farber receives MLSC grant to expand cancer imaging research

The Massachusetts Life Sciences Center has awarded Dana-Farber Cancer Institute a $10 million grant to support the expansion of its pioneering cancer imaging research program.

1 Feb 2012

Vertex receives FDA approval for Kalydeco to treat rare form of CF

The U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.

1 Feb 2012

Researchers identify two genetic mutations responsible for brain cancer in children

An international research team led by the Research Institute of the McGill University Health Centre (RI MUHC) has made a major genetic breakthrough that could change the way pediatric cancers are treated in the future.

30 Jan 2012

Everist Genomics' CardioDefender Device to be featured at Wearable Technologies Conference

Everist Genomics announced today that Executive Vice Chairman Alex Charlton will speak about its breakthrough CardioDefender Device at the Wearable Technologies Conference, January 30, 2012, in Munich.

30 Jan 2012

Lab21 acquires new real time PCR technology

Lab21 Limited, the global specialist in personalized medicine and clinical diagnostics, today announces the completion of a worldwide license from Cooperative Diagnostics to use its suite of patents and expertise for the development of its growing pipeline of molecular diagnostic kits. Financial details of the agreement were not disclosed.

23 Jan 2012

WSU professors receive NSF grant to develop math model of liver metabolism

Predicting problems in one of the body's most complex organs soon may become easier because of work being done by Wayne State University researchers.

20 Jan 2012

BJALCF receives $1 million in grants for 2012 Lung Cancer Research

Just two months shy of marking its 7-year anniversary, BJALCF announced today that it has awarded over $1 million in grants for 2012 Lung Cancer Research. BJALCF has made a promise to the Lung Cancer Community to fund only immediate results-oriented projects or programs promising to catalyze progress through early detection, genetic testing, drug discovery and patient-focused outcomes.

17 Jan 2012

Saladax increases claims in immunoassay space to 15 patents

Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that it has been issued six patents within the last 12 months, bringing the company's total to 15 issued U.S. patents, all of which contain broad claims in the immunoassay space.

11 Jan 2012

Personalized medicine could offer a valuable tool to help combat the diabetic epidemic

With the trend in healthcare moving toward an era of personalized medicine, there is much anticipation and hope that customized approaches to prevention and treatment based on a person's genetic make-up will result in better health outcomes. Some advances, most notably with prevention and treatment of breast and colon cancer, have been widely heralded, raising questions about the potential for personalized medicine for other common diseases, such as diabetes.

10 Jan 2012

HDC, NeoGenomics sign worldwide licensing agreement to develop LDT

Health Discovery Corporation, a molecular diagnostics leader in the use of patent protected advanced mathematical techniques for personalized medicine, has entered into an exclusive worldwide licensing agreement with NeoGenomics, Inc. for laboratory developed tests in the Field of hematopoietic and solid tumor cancers excluding breast cancer, which was previously licensed to Quest Diagnostics and Smart Personalized Medicine and excluding cancer of the retina which was previously committed to Retinalyze, LLC.

9 Jan 2012

TRON uses Ingenuity Variant Analysis to identify cancer driver variants

Ingenuity Systems, a leading provider of information and analysis solutions for life science researchers, today announced that TRON has used Ingenuity Variant Analysis to identify cancer driver variants that inform the development of an experimental individualized RNA-based therapeutic.

9 Jan 2012